Affymetrix Aims to Diversify Revenue Stream With Upcoming DMET Service, Navigenics Pact | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
With the market for DNA gene expression research waning, Affymetrix is broadening its services offerings to include drug metabolism testing in the short term and personal genetics in the longer term through a collaboration with consumer genotyping startup Navigenics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.